Jacobio Pharmaceuticals Group (77V) Stock Overview
An investment holding company, engages in the in-house discovery and development of oncology therapies in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
77V Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Jacobio Pharmaceuticals Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.51 |
| 52 Week High | HK$1.13 |
| 52 Week Low | HK$0.44 |
| Beta | 0.38 |
| 1 Month Change | -31.29% |
| 3 Month Change | -20.47% |
| 1 Year Change | -17.21% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 179.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 77V | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.0% | 0.3% | 0.7% |
| 1Y | -17.2% | -8.2% | 2.0% |
Return vs Industry: 77V underperformed the German Biotechs industry which returned -8.5% over the past year.
Return vs Market: 77V underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 77V volatility | |
|---|---|
| 77V Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 77V's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 77V's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 67 | Yinxiang Wang | www.jacobiopharma.com |
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People’s Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic malignancies; JAB-BX102, a humanized monoclonal antibody against CD73, which is in a Phase I/IIa trial; JAB-2485, a highly selective Aurora Kinase A (AURKA) inhibitor that is in a Phase I/IIa trial for solid tumors; JAB-23E73, an oral small-molecule pan-KRAS inhibitor that is in a Phase I trial for KRAS-mutant PDAC, CRC, NSCLC, and solid tumors; and JAB-30355, a bioavailable small molecule p53 reactivator that is in a Phase I trial for the treatment of patients with locally advanced or metastatic solid tumors. It is also developing IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications.
Jacobio Pharmaceuticals Group Co., Ltd. Fundamentals Summary
| 77V fundamental statistics | |
|---|---|
| Market cap | €420.37m |
| Earnings (TTM) | -€18.49m |
| Revenue (TTM) | €6.78m |
Is 77V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 77V income statement (TTM) | |
|---|---|
| Revenue | CN¥53.53m |
| Cost of Revenue | CN¥593.00k |
| Gross Profit | CN¥52.93m |
| Other Expenses | CN¥198.91m |
| Earnings | -CN¥145.98m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 98.89% |
| Net Profit Margin | -272.73% |
| Debt/Equity Ratio | 12.3% |
How did 77V perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/29 08:31 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jacobio Pharmaceuticals Group Co., Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yu Wu | CMB International Securities Limited |
| Linhai Zhao | Goldman Sachs |